Explore these ideas and much more!

Explore related topics

Medical Tidbits,Allergan Launches Bold Initiative to Help U.S. Military Servicewomen Access LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at Military Treatment Facilities

Medical Tidbits,Allergan Launches Bold Initiative to Help U.S. Military Servicewomen Access LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at Military Treatment Facilities

Medical Tidbits,Medtronic IN.PACT Admiral DEB Receives CE Mark for Treatment of AV Access In Patients with End-Stage Renal Disease

Medical Tidbits,Medtronic IN.PACT Admiral DEB Receives CE Mark for Treatment of AV Access In Patients with End-Stage Renal Disease

Medical Tidbits, FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US

Medical Tidbits, FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US

Sobi™ enters into new distribution agreement with Valeant for Ammonul®

Sobi™ enters into new distribution agreement with Valeant for Ammonul®

Medical Tidbits,Astellas Granted Label Extension for QUTENZA[TM] (capsaicin 8% patch) to Include Treatment of Diabetic Patients With Peripheral Neuropathic Pain (PNP) 

Medical Tidbits,Astellas Granted Label Extension for QUTENZA[TM] (capsaicin 8% patch) to Include Treatment of Diabetic Patients With Peripheral Neuropathic Pain (PNP) 

Medical Tidbits, Merck and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer

Medical Tidbits, Merck and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer

Medical Tidbits,Bionik Laboratories Advances Development of Lead Product ARKE GEN2 – Second Generation Robotic Lower-Body Exoskeleton

Medical Tidbits,Bionik Laboratories Advances Development of Lead Product ARKE GEN2 – Second Generation Robotic Lower-Body Exoskeleton

Medical Tidbits, Vertex Receives Australian Approval for ORKAMBI(R) (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation

Medical Tidbits, Vertex Receives Australian Approval for ORKAMBI(R) (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation

Pinterest
Search